Investor Relations

Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the company's lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (enoxaparin sodium injection). The company’s development pipeline includes a generic version of Copaxone® (glatiramer actetate), also in collaboration with Sandoz, follow-on biologics in collaboration with Baxter, and M402, a novel oncology drug candidate in Phase 1/2 clinical development